Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: UCB 44212

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 10 Oct 2006 Interim results from two phase IIa clinical trials (N01191 and N01192) in patients with epilepsy have been added to the adverse events and Epilepsy therapeutic trials sections
  • 21 Nov 2005 Data presented at the 26th International Epilepsy Congress (IEC-2005) have been added to the Epilepsy and seizure disorders pharmacodynamics section ,,
  • 18 Apr 2005 Data presented at the 9th International Congress of Parkinson's Disease and Movement Disorders (PDMD-2005) have been added to the Parkinson's disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top